In this issue of Clinical Watch, we discuss new antipsychotic medication formulations to tailor the management of schizophrenia and suggest prior authorization criteria for a new treatment for Cushing’s disease. Lastly, we review claims data to identify the trends for use of Dupixent®.
For more information about a topic, please contact Janelle Sheen, Karen Powell or Mary-Beth Plum. Be sure to watch for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.
Related Flipbooks








In this issue of Clinical Watch, we discuss nitrosamine impurities found in widely used medications and suggest prior authorization criteria for a new treatment for heavy menstrual bleeding

In this issue of Clinical Watch, we highlight the use of diabetes drugs in the treatment of heart failure and suggest prior authorization criteria for the first approved treatment of plexiform neurofi

Customer expectations have grown exponentially. Companies must deliver seamless, real-time, personalized experiences to meet them. Find out what customers are saying about their experiences in Telecom

Customer expectations have grown exponentially. Companies must deliver seamless, real-time, personalized experiences to meet them. Find out what customers are saying about their experiences in Retail

Customer expectations have grown exponentially. Companies must deliver seamless, real-time, personalized experiences to meet them. Find out what customers are saying about their experiences in Media